Hoxton Ventures — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Wilmington, US
Jakub Chudik(Executive Officer, Director)Matej Novak(Executive Officer, Director)
Board seatRobert Karol Kniaz· per SEC Form D
Co-investorsCredo Ventures
Phagos develops phage therapy treatments as an alternative to antibiotics, using its Alphagos platform that combines microbiology and AI to design targeted bacterial medicines against antimicrobial resistance.
AgTechAI & Machine LearningBiotechIvry-Sur-Seine, FR
Alexandros Pantalis(Executive Officer, Director)inAdèle James(CTO)inAdele James(Director)
BoardXin Ma(Director)Geoffroy Dubus(Director)
Board seatRobert Kniaz· per SEC Form D
Co-investorsAcurio VenturesBeyond CapitalEntrepreneur FirstAgFunderCapagroCitizen Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.